PL1991201T3 - Nebulizowane antybiotyki do terapii inhalacyjnej - Google Patents

Nebulizowane antybiotyki do terapii inhalacyjnej

Info

Publication number
PL1991201T3
PL1991201T3 PL07703355T PL07703355T PL1991201T3 PL 1991201 T3 PL1991201 T3 PL 1991201T3 PL 07703355 T PL07703355 T PL 07703355T PL 07703355 T PL07703355 T PL 07703355T PL 1991201 T3 PL1991201 T3 PL 1991201T3
Authority
PL
Poland
Prior art keywords
nebulised
antibiotics
inhalation therapy
inhalation
therapy
Prior art date
Application number
PL07703355T
Other languages
English (en)
Inventor
Manfred Keller
Aslihan Akkar
Original Assignee
Pari Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pari Pharma Gmbh filed Critical Pari Pharma Gmbh
Publication of PL1991201T3 publication Critical patent/PL1991201T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07703355T 2006-02-10 2007-02-08 Nebulizowane antybiotyki do terapii inhalacyjnej PL1991201T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06002734 2006-02-10
EP07703355.3A EP1991201B1 (en) 2006-02-10 2007-02-08 Nebulised antibiotics for inhalation therapy
PCT/EP2007/001080 WO2007090646A1 (en) 2006-02-10 2007-02-08 Nebulised antibiotics for inhalation therapy

Publications (1)

Publication Number Publication Date
PL1991201T3 true PL1991201T3 (pl) 2018-09-28

Family

ID=36607472

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07703355T PL1991201T3 (pl) 2006-02-10 2007-02-08 Nebulizowane antybiotyki do terapii inhalacyjnej

Country Status (19)

Country Link
US (1) US20090025713A1 (pl)
EP (1) EP1991201B1 (pl)
JP (1) JP2009526003A (pl)
CN (1) CN101389313A (pl)
AU (1) AU2007213983B2 (pl)
BR (1) BRPI0707641A2 (pl)
CA (1) CA2641827A1 (pl)
CY (1) CY1120284T1 (pl)
DK (1) DK1991201T3 (pl)
ES (1) ES2671342T3 (pl)
HU (1) HUE037773T2 (pl)
LT (1) LT1991201T (pl)
MX (1) MX2008010222A (pl)
PL (1) PL1991201T3 (pl)
PT (1) PT1991201T (pl)
RU (1) RU2008136460A (pl)
SI (1) SI1991201T1 (pl)
TR (1) TR201807714T4 (pl)
WO (1) WO2007090646A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103478A1 (en) * 2003-05-20 2004-12-02 Collins James F Ophthalmic drug delivery system
US8012136B2 (en) * 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0602980D0 (en) * 2006-02-14 2006-03-29 Optinose As Delivery device and method
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US20090212133A1 (en) * 2008-01-25 2009-08-27 Collins Jr James F Ophthalmic fluid delivery device and method of operation
US20100055045A1 (en) * 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
AU2009302478B2 (en) * 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
CN102325532B (zh) * 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
US8168597B2 (en) 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
JP5960434B2 (ja) * 2009-02-18 2016-08-02 アラダイム コーポレーション 肺送達のためのpH調節された製剤
ES2457442T3 (es) * 2009-05-08 2014-04-25 Pari Pharma Gmbh Formulaciones farmacéuticas concentradas estabilizadoras de los mastocitos
CN102711760A (zh) * 2009-08-19 2012-10-03 Mpex医药有限公司 雾化抗生素用于治疗慢性阻塞性肺病的用途
LT2473170T (lt) * 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
AU2015275224C1 (en) * 2009-09-04 2017-11-16 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
JP5600056B2 (ja) * 2010-02-25 2014-10-01 参天製薬株式会社 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤
MX336260B (es) * 2010-07-12 2016-01-13 Xellia Pharmaceuticals Aps Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
AU2011278934B2 (en) 2010-07-15 2015-02-26 Eyenovia, Inc. Drop generating device
WO2012009702A1 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
MX2013000604A (es) 2010-07-15 2013-07-05 Corinthian Ophthalmic Inc Suministro oftálmico de fármaco.
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CN104487028A (zh) 2011-12-12 2015-04-01 艾诺维亚股份有限公司 高模量聚合物喷射器机构、喷射器装置及其使用方法
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US10064583B2 (en) 2013-08-07 2018-09-04 Covidien Lp Detection of expiratory airflow limitation in ventilated patient
KR20160127712A (ko) * 2013-10-30 2016-11-04 인스피릭스 아이엔씨. 다제내성 결핵 치료를 위한 흡입 에어로졸 면역화학요법
PL3104853T3 (pl) * 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
JP2017505348A (ja) 2014-02-10 2017-02-16 パタラ ファーマ リミテッド ライアビリティ カンパニー 肺疾患治療のための肥満細胞安定剤
CN107708875A (zh) 2015-06-10 2018-02-16 斯坦福设备有限公司 气雾剂产生
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
HUE060119T2 (hu) * 2016-05-31 2023-02-28 Spexis Ag Béta-hairpin peptidomimetikum elasztáz gátló hatással és annak aeroszolos adagolási formái
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
EP3484458A4 (en) * 2016-07-16 2020-04-15 Lauranell Harrison Burch METHOD FOR TREATING MUCOVISCIDOSIS AND OTHER DISEASES WITH EFFECT ON THE MUCOSA
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
CN107669636A (zh) * 2016-09-30 2018-02-09 青岛大学 一种氨溴索喷雾剂
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
KR102643190B1 (ko) 2017-06-10 2024-03-04 아이노비아 인코포레이티드 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 디바이스들
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
CN109419785A (zh) * 2017-08-31 2019-03-05 正大青春宝药业有限公司 一种鱼腥草提取物制剂及其应用
IT201900006104A1 (it) * 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Metodo di preparazione di un prodotto a base di chitosano
CN112569211A (zh) * 2019-09-27 2021-03-30 盈科瑞(天津)创新医药研究有限公司 一种吸入用加替沙星溶液及其制备方法
WO2021119513A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN114948914B (zh) * 2022-06-30 2024-04-02 北京新领先医药科技发展有限公司 一种盐酸莫西沙星雾化吸入用溶液剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ293747B6 (cs) * 1995-12-21 2004-07-14 Pfizer Inc. Vodný farmaceutický roztok vhodný pro injekční podávání hostiteli a jeho použití
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
NZ509328A (en) * 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
US6070575A (en) * 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6397838B1 (en) * 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6962151B1 (en) * 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US6550472B2 (en) * 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
WO2003012565A1 (en) * 2001-07-31 2003-02-13 Chrysalis Technologies Incorporated Method and apparatus for generating a volatilized liquid
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
US6702997B2 (en) * 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
DE10239321B3 (de) * 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
EP1628637A2 (en) * 2003-05-30 2006-03-01 Alza Corporation Method of pulmonary administration of an agent
KR101137052B1 (ko) * 2003-11-17 2012-04-24 노바르티스 아게 인공호흡기 회로에 대한 에어로졸의 효과적인 주입
WO2005065435A2 (en) * 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CA2559208A1 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
HUE030419T2 (en) * 2005-05-18 2017-05-29 Horizon Orphan Llc Aerosolized fluoroquinolones and their uses

Also Published As

Publication number Publication date
EP1991201B1 (en) 2018-03-28
TR201807714T4 (tr) 2018-06-21
CN101389313A (zh) 2009-03-18
SI1991201T1 (en) 2018-08-31
AU2007213983A1 (en) 2007-08-16
JP2009526003A (ja) 2009-07-16
CA2641827A1 (en) 2007-08-16
DK1991201T3 (en) 2018-06-14
RU2008136460A (ru) 2010-03-20
AU2007213983B2 (en) 2012-09-20
LT1991201T (lt) 2018-07-25
MX2008010222A (es) 2008-10-17
EP1991201A1 (en) 2008-11-19
BRPI0707641A2 (pt) 2011-05-10
PT1991201T (pt) 2018-06-12
CY1120284T1 (el) 2019-07-10
US20090025713A1 (en) 2009-01-29
WO2007090646A1 (en) 2007-08-16
HUE037773T2 (hu) 2018-09-28
ES2671342T3 (es) 2018-06-06

Similar Documents

Publication Publication Date Title
HUE037773T2 (hu) Porlasztott antibiotikumok inhalációs terápiához
IL197316A0 (en) Buprenophine-wafer for drug substitution therapy
EP2101855A4 (en) ADMINISTRATION OF ANTI-THERAPY
ZA200901376B (en) Trauma therapy
PL1973598T3 (pl) Aparat do terapii lekowej aktywowanej światłem
IL195247A0 (en) Inhaler
PL2007457T3 (pl) Inhalator
IL236360A0 (en) Inhalable medicine
ZA200806929B (en) Nebulizer formulation
GB2434754B (en) Inhaler
IL197125A0 (en) Drug combinations for treating airway diseases
GB2461008B (en) Nicotine inhalation device
EP2123295A4 (en) THERAPEUTIC AGENT FOR INTERSTITIAL PNEUMONIA
AP2006000208S (en) Inhaler
AU311491S (en) Inhaler
PH32006000029S1 (en) Atomizer for inhaler
GB2437806B (en) Novel therapeutic delivery system
GB0524945D0 (en) Medicament inhaler
PH32006000910S1 (en) Inhaler
GB0612693D0 (en) Inhaler
PH32006000619S1 (en) Inhaler
PH32006000028S1 (en) Inhaler
GB0608669D0 (en) Novel Therapeutic Delivery System
GB0613459D0 (en) Novel therapeutic delivery system
GB0609414D0 (en) Therapy